Skip to content
Biotechnology

FY25 Half Year Results – Shareholder Update

BTC Health Limited (ASX:BTC) 2 mins read

Highlights:

• BTC statutory profit after tax of $4.9m (1H FY24: $1.7m)
• BTC and investee companies consolidated 1H FY25 performance:

• revenue up 9% to $5.3m (1H FY24: $4.9m) 
• gross profit up 6% to $2.3m (1H FY24: $2.2m)
• operating expenses remain well controlled at $2.1m (1H FY24: $2.1m)
• EBITDA of $0.2m (1H FY24: $0.1m)
• net cash reserves of $2.7m (1H FY24: $2.4m)

• Investee businesses greatly diversified and strengthened with:

• acquisition of the Corcym heart valve business – adding $3.6m revenue per annum
• award of a $5m 5-year ECMO contract with Royal Childrens’ Hospital - Melbourne
• Rhythmic and Elasto-Q infusion pumps approved for private health reimbursement
• Bronchitol and Aridol license for Aus/NZ extended indefinitely

Executive Chairman and Managing Director Dr Richard Treagus commented, "We have significantly strengthened and diversified the business over the last 6 months, and with a solid foundation established, we are well positioned to continue the positive momentum throughout 2025.”

READ THE FULL ANNOUNCEMENT HERE

READ THE INVESTOR PRESENTATION HERE


About us:

About BTC Health
BTC Health is a registered Pooled Development Fund and has investments in three core medical companies:

- BTC Speciality Health, which is responsible for the commercialisation and distribution of medical devices and medical consumables in the therapeutic categories of acute pain management and neurospinal surgery.
- BTC Pharma, which undertakes the registration, development, sales and marketing of specialised pharmaceutical medicines, that serve niche markets and rare diseases.
- BTC Cardio, which is dedicated to the marketing and distribution of highly specialised cardiovascular medical equipment and single-use consumable products used by cardiac surgeons and critical care experts.


Contact details:

For more information, please contact:

BTC Health Limited (ASX:BTC)
Dr Richard Treagus 
Executive Director
T:  +61 417 520 509 
E: [email protected]

Tracy Weimar
Company Secretary
T: +61 3 9692 7222
E: t[email protected]

Investor Relations
The Capital Network 
Julia Maguire
T: +61 2 7257 7338
E: [email protected]

More from this category

  • Biotechnology, Business Company News
  • 19/02/2026
  • 22:53
Ecopha Group Inc

Ecopha Group Inc. Recognised as One of the Most Innovative Companies to Watch in 2026 by The CEO Vision.

Key Facts: • Recognised by CEO Vision as one of the Most Innovative Companies to Watch in 2026• Incorporated in Delaware, USA in 2024…

  • Contains:
  • Biotechnology, Medical Health Aged Care
  • 19/02/2026
  • 12:50
Q-Sera

Improving laboratory management and patient outcomes – Q-Sera announces first product launch of its RAPClot(TM) rapid serum blood collection tube technology in Japan

Melbourne, Australia – February 19, 2026 – Q-Sera Pty Ltd, an Australian venture-backed company, today announced that leading Japanese medical device company, Terumo Corporation has launched VenoJect II RAPClotTM evacuated blood collection tubes in the Japanese market. These next-generation tubes incorporate Q-Sera’s patent protected technology and will improve laboratory management and patient outcomes. Even in anticoagulated blood, RAPClot™ rapid serum tubes rapidly produce high quality serum in five minutes. In the case of the VenoJect II RAPClot tubes, formulated to clot up to 6U/ml heparin. This is the first real innovation in the Japanese blood collection tube market in decades,…

  • Biotechnology, Business Company News
  • 12/02/2026
  • 12:22
Jane Morgan Management

BlinkLab Limited (ASX:BB1) Expands Pivotal FDA Trial Network to Nine Elite U.S. Sites Ahead of Imminent Study Commencement

12February 2026 – Sydney, Australia | BlinkLab Limited (ASX:BB1), a leader in AI-powered digital diagnostics, has expanded its U.S. clinical footprint with the onboarding…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.